Drug firm Alembic Pharmaceuticals today said the US health regulator has granted orphan drug designation to its associate company Rhizen Pharmaceuticals SA's RP6530 used for treatment of cancer. The US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing.

The USFDA grants orphan drug designation to a drug or biological product int ..